Loading...
•
Jun 30, 2021
Alector Q2 2021 Earnings Report
Alector reported second quarter 2021 financial results, highlighted by a global collaboration with GSK and encouraging Phase 2 data for AL001 in FTD-GRN.
Key Takeaways
Alector's Q2 2021 saw a collaboration with GSK to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, along with encouraging Phase 2 data for AL001 in FTD-GRN. The company's cash, cash equivalents and investments totaled $319.6 million as of June 30, 2021.
Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer’s Association International Conference (AAIC).
Announced global collaboration with GSK to co-develop and co-commercialize progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases
Once monthly treatment with 60mg/kg of AL001 was shown to have a favorable safety profile and resulted in sustained elevation of progranulin to normal levels for greater than one year.
Clinical outcome assessments of AL001-treated patients showed slowing of clinical progression by 47% compared to a matched control cohort of participants from the Genetic FTD Initiative (GENFI2).
Revenue by Segment
Forward Guidance
Based on the company's cash position as of the end of the second quarter, combined with the anticipated net proceeds expected from the GSK collaboration beginning in the third quarter of 2021, Alector anticipates sufficient cash to fund currently planned operations into mid-2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...